Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Bad financial results growth rate -8.1% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (6.7%)
  • Dividend yield for the last twelve months 4.0%
  • Free cash flow yield -0.2% (LTM)
  • Share price is 10.4% higher than minimum and 39.0% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (9.8x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (+0.1%)81.09
year average price 90.83  


year start price 118.64 2024-09-18

max close price 118.64 2024-09-18

min close price 73.47 2025-05-14

current price 81.09 2025-09-17
Common stocks: 2 528 810 012

Dividend Yield:  4.0%
FCF Yield LTM: -0.2%
EV / LTM EBITDA: 9.8x
EV / EBITDA annualized: 9.5x
Last revenue growth (y/y):  -1.9%
Last growth of EBITDA (y/y):  -14.3%
Historical revenue growth:  +3.9%
Historical growth of EBITDA:  +9.5%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 205 061
Net Debt ($m): 26 847
EV (Enterprise Value): 231 908
EBITDA LTM ($m): 23 763
EV / LTM EBITDA: 9.8x
Price to Book: 4.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-09-16seekingalpha.com

Merck: Buy This Dividend Powerhouse While It's Cheap

2025-09-11zacks.com

Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?

2025-09-11businesswire.com

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease

2025-09-11reuters.com

Britain defends investment record as Merck scraps labs over pharma environment

2025-09-11proactiveinvestors.co.uk

Merck axes £1bn London lab in blow to UK life sciences

2025-09-09zacks.com

Will Merck's Cost Cuts and New Drug Approvals Ease Headwinds?

2025-09-04seekingalpha.com

Merck & Co., Inc. (MRK) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

2025-09-03businesswire.com

Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions

2025-09-03zacks.com

MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline

2025-09-02businesswire.com

Merck's Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data